Newswire (Published: Wednesday, August 28, 2019, Received: Wednesday, August 28, 2019, 5:10:50 PM CDT)

Word Count: 423

2019 AUG 28 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Daily -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting out of Lexington, United States, by NewsRx editors, research stated, “Prostate cancer is the most prevalent type of cancer in men. The etiology of prostate cancer development and the mechanisms underlying androgen-independent progression remains to be further investigated.”

Our news journalists obtained a quote from the research from the University of Kentucky, “There are many known targets for prostate cancer therapy including the androgen receptor (AR) axis, but resistance eventually develops in advanced disease suggesting the need to better understand mechanisms of resistance and consideration of multi-targeted therapy. Mechanisms contributing to resistance may include gene amplifications, gene mutations, AR splice variants, and changes in expression of androgen receptor co-regulatory proteins. Given the limitations of approved therapies, further study of additional potential targets is warranted. This review focuses on the roles of autophagy pathway, p62, Yes-associated protein (YAP), cancer stem cells, and epigenetics. Therapies targeting these potential mechanisms of resistance may interact with currently approved therapies either additively or synergistically.”

According to the news editors, the research concluded: “Thus, the study of combination therapy against multiple targets may be critically important to achieve more impact against lethal forms of prostate cancer resistant to all approved current therapies.”

For more information on this research see: New developments in mechanisms of prostate cancer progression. Seminars In Cancer Biology, 2018;57():111-116. Seminars In Cancer Biology can be contacted at: Academic Press LTD Elsevier Science LTD, 24-28 Oval Rd, London NW1 7DX, England. (Elsevier - www.elsevier.com; Seminars In Cancer Biology - http://www.journals.elsevier.com/seminars-in-cancer-biology/)

Our news journalists report that additional information may be obtained by contacting R.S. DiPaola, College of Medicine, University of Kentucky, Lexington, Kentucky 40506, United States. Additional authors for this research include M. Clementino, D. Kim, L. Wang, A. Verma, X. Shi, Z. Zhang and R.S DiPaola.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.semcancer.2018.09.003. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Seminars In Cancer Biology is: Academic Press LTD Elsevier Science LTD, 24-28 Oval Rd, London NW1 7DX, England.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

University of Kentucky

Places

North America
Northern Europe
United Kingdom
United States
Americas
Europe
England
Kentucky
London
Lexington

Subjects

Science and Technology
      Scientific Research
            Medical Research
      Sciences
            Natural Sciences
                  Biology
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research